OncoMed Pharmaceuticals Inc. started the new year with more bad clinical news – the failure of yet another asset, this time the Celgene Corp.-partnered anti-RSPO3 antibody rosmantuzumab – and the departure of ailing CEO Paul Hastings.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?